Novel Technologies and Emerging Therapies for Precision Medicine

Scroll to the bottom of this page to obtain CME/CE credit

Lysosomal & Rare Disorders Research & Treatment Center

GRIDS-2021

Novel Technologies and Emerging Therapies for Precision Medicine

July 16, 2021 – July 15, 2022

NO LONGER AVAILABLE FOR CREDIT

Continuing Education Information

This continuing education activity is provided through collaboration between Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for Physicians, Physician Assistants, Nurses, Nurse Practitioners, Genetic Counselors as well as a statement of participation for other attendees.

Faculty

Shoshana Revel-Vilk, MD, PhD
Shaare Zedek Medical Center, Israel

Neil Joseph Weinreb, MD
University of Miami, FL, USA

Learning Outcomes

At the end of this activity, participants should be able to:

  • Detail the different technologies used in digital health.
  • Discuss the benefits and challenges of the different technologies of digital health.
  • Explain projects of digital health in Gaucher disease.
  • Identify some of the different clinical manifestations of representative lysosomal
    storage disorders (LSDs) and how persistent unmet needs for treatment are driving the
    search for innovative small molecule treatments.
  • Identify the increasing numbers of non-chaperone small molecule oral therapies as
    alternative treatments for disorders currently treated with intravenous ERTs and as novel treatments for diseases in which ERT is either insufficient or inapplicable.

Disclosures

AffinityCE staff, LDRTC staff, planning and review committees have no financial interests to disclose and do not recommend the use of products outside of the FDA approved labelling.

Faculty disclosures

Neal Joseph Weinreb, MD
Sanofi Genzyme, Takeda Shire, Pfizer Corporation: Consultant and Speaker, Scientific Advisory Board

Conflict of interest for Dr. Weinreb was resolved through peer review of content by a non-conflicted reviewer.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 1.5 hours of continuing nursing education credit.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselors
Category 2 CEU

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a Statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Commercial Support

Educational Support for this activity was provided by Takeda Pharmaceuticals USA, Inc., Genzyme Corporation, Spark Therapeutics, Inc., CHIESI USA, Inc., Amicus Therapeutics, Inc., Pfizer Inc., Ultragenyx Pharmaceutical, Inc., and AVROBIO, Inc.

Participation Costs

There is no cost to participate in these CE sessions.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Send customer support requests to cds_support+ldrtc@affinityced.com.